Bispecific antibodies Horizons Infosheet

This Horizons Infosheet contains information on bispecific antibodies, a type of treatment being investigated for use in myeloma. Bispecific antibodies are also called T cell engagers. Several bispecific antibodies are being developed for treatment of myeloma, including teclistamab, talquetamab and elranatamab.

Update June 2024: since this Infosheet was updated, the National Institute for Health and Care Excellence (NICE) has approved the bispecific antibody elranatamab for use in England and Wales for eligible myeloma patients at fourth line and beyond. For more information read our Patient Advocacy blog here.

This Horizons Infosheet covers key questions and topics about bispecific antibodies, including:

  • What are bispecific antibodies?
  • How do bispecific antibodies work?
  • How are bispecific antibodies given?
  • What evidence exists to support the use of bispecific antibodies?
  • What are the possible known side effects of bispecific antibodies?
  • Are bispecific antibodies currently available in any UK clinical trials?
  • Availability of bispecific antibodies in the UK
  • Future directions

Key points you can read about in this Infoguide include:

  • Bispecific antibodies are a new group of treatments being investigated for use in myeloma
  • There are several bispecific antibodies in development for treatment of myeloma
  • Bispecific antibodies attach to myeloma cells and to cells in the immune system called T cells
  • Bispecific antibodies bring the T cells into close contact with myeloma cells. The T cells are then made active, and are able to kill the myeloma cells
  • Bispecific antibodies have shown anti-myeloma effects in a number of clinical trials in patients with relapsed and/or refractory myeloma, and further clinical trials are underway or planned
  • Side effects seen so far with bispecific antibodies have included infections, fever, reduced levels of blood cells, reduced blood pressure, neurological symptoms, gastrointestinal symptoms, altered taste, and changes to skin or nails

Bispecific antibodies Horizons Infosheet

PDF / 253KB Download
Close-up photograph of a hand holding a mobile phone.

Stay in touch

We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.